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Background: c-Jun NH2-terminal kinases (JNKs) are strongly activated by a stressful cellular environment, such as
chemotherapy and oxidative stress. Autophagy is a protein-degradation system in which double-membrane
vacuoles called autophagosomes are formed. The autophagy-related gene Beclin 1 plays a key role in this process.
We previously found that autophagy was induced by dihydroartemisinin (DHA) in pancreatic cancer cells. However,
little is known about the complex relationship between ROS, JNK activation, autophagy induction, and Beclin 1
expression.
Methods: Cell viability and CCK-8 assays were carried out to determine the cell proliferation; small interfering RNAs
(siRNAs) were used to knockdown c-Jun NH2-terminal kinases (JNK1/2) genes; western blot was performed to detect
the protein expression of LC3, JNK, Beclin 1, caspase 3 and β-actin; production of intracellular ROS was analyzed
using FACS flow cytometry; autophagy induction was confirmed by electron microscopy.
Results: In the present study, we explored the role of DHA and Beclin 1 expression in autophagy. DHA-treated cells
showed autophagy characteristics, and DHA also activated the JNK pathway and up-regulated the expression of
Beclin 1. Conversely, blocking JNK signaling inhibited Beclin 1 up-regulation. JNK activation was found to primarily
depend on reactive oxygen species (ROS) resulting from the DHA treatment. Moreover, JNK pathway inhibition and
Beclin 1 silencing prevented the induction of DHA-induced autophagy.
Conclusions: These results suggest that the induction of autophagy by DHA is required for JNK-mediated Beclin 1
expression.
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c-Jun NH2-terminal kinases (JNKs) are strongly activated
by a variety of stressful cellular environments, such as
chemotherapy and oxidative stress, and induce growth in-
hibition or cell death [1,2]. The JNK signaling pathway has
also been involved in stress-induced apoptosis [3,4], includ-
ing neuronal death in models of excitotoxicity and stroke
[5-7]. JNK is a ‘stress-activated protein kinase’ and plays a* Correspondence: wuliang_227@163.com
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stated.pivotal role in both inflammation and cell death [8], with
the JNK-induced apoptotic response being mediated, in
part, by the expression and/or phosphorylation of proteins
belonging to the Bcl-2-related family [9-12]. JNK have a
number of targets, including the transcription factor c-Jun,
the forkhead transcription factor, and other pro- or anti-
apoptotic factors, such as Bax and Bcl-2 [13,14].
Autophagy is a lysosomal pathway involved in the deg-
radation of cytoplasmic macromolecules (such as proteins),
and organelles. This process was well preserved during evo-
lution. Although autophagy became a very seductive topic
in cancer treatment research, the current literature about
autophagy is very confusing due to the association of au-
tophagy with both cell survival and death. Some studiesThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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tions, such as metabolic stress, energy need, and chemo-
therapy [15,16]. Furthermore, several recent reports
indicated that reactive oxygen species (ROS) induced au-
tophagy in response to chemotherapy [17,18]. Studies also
showed that autophagy promoted cancer cell survival
through the generation of metabolic substrates maintaining
cellular activity, thereby limiting chemotherapy cytotoxicity
[19]. However, the role of autophagy in the efficacy of anti-
cancer drugs remains to be defined. Accordingly, this study
aimed to further elucidate the role of treatment-induced
autophagy in pancreatic cancer cells.
Beclin 1 (the ortholog of yeast Atg6) was the first
mammalian autophagy protein to be identified [20], and
is a haplo-insufficient tumor suppressor gene. Its gene is
frequently mono-allelically deleted in sporadic cancers
affecting the prostate, ovaries and breast [21]. Beclin 1
could play a role in recruiting cytosolic proteins for au-
tophagic degradation, or by supplying the autophago-
somes with membrane components [22]. Beclin 1 is a
member of a Class III PI3K complex involved in autop-
hagosome formation. It mediates the localization of the
other proteins involved in autophagy to the pre-
autophagosomal membrane [22]. Beclin 1 is also a key
factor determining the autophagic or apoptotic fate of
cells [23]. Beclin 1 interacts with members of the anti-
apoptotic Bcl-2 family via its BH3 domain; Interacting
with Bcl-2 proteins competitively inhibits pre-
autophagosomal structure formation, thereby inhibiting
autophagy [24].
Artemisinin extracted from Artemisia annua, a Chin-
ese medicinal herb, is extremely effective against malaria,
with only a few adverse effects. Dihydroartemisinin
(DHA) is synthesized from artemisinin. It is more sol-
uble in water, and it is also more effective against mal-
aria than artemisinin. More interestingly, it has also
been found to be an effective anti-cancer drug [25-28].
Furthermore, it has been showed that DHA inhibited
cell growth and induced apoptosis in pancreatic cancer
cells, and that this effect was dose- and time-dependent.
Artemisinin has been shown to contain an endoperoxide
bridge, which reacts with iron to form ROS. Interest-
ingly, we observed that DHA also activates autophagy in
pancreatic cancer cells, and various findings indicate that
a number of antineoplastic therapies induce a type of
protective, pro-survival autophagy [29-31]. Moreover,
ROS-mediated JNK activation is required for the forma-
tion of autophagosomes [32]. However, the mechanism
by which JNK induces autophagy and the association
with anticancer therapy remains mostly unknown.
Therefore, in this present study, we explored the in-
volvement of JNK activation and Beclin 1 expression in
DHA-induced autophagy. The aim of the present study
was to assess the exact relationships between Beclin 1expression, JNK pathway activation, and autophagy. We
demonstrated that DHA-induced autophagy involved
the JNK pathway in pancreatic cancer cell lines, resulting
in increased expression of Beclin 1. SP600125 or small
interfering RNAs (siRNAs) targeting JNK1/2 inhibited
the up-regulation of Beclin 1, as well as autophagy. Re-
sults from the present study provide further clues
explaining Beclin 1 regulation in autophagy induced by
cancer treatments.
Materials and methods
Cell lines and culture
The human pancreatic cancer cell lines BxPC-3 (CRL-
1687) and PANC-1 (CRL-1469) were purchased
from the American Type Culture Collection (ATCC,
Manassas, USA). The cells were cultured in RPMI 1640
(SH30809.01B, Hyclone, Thermo Fisher Scientific, Wal-
tham, MA, USA) supplemented with 10% fetal bovine
serum (16000, GIBCO, Invitrogen Inc., Carlsbad, CA,
USA), 100 units/mL penicillin and 100 μg/mL strepto-
mycin (Invitrogen, 15070–063). Cells were maintained at
37°C in a humidified atmosphere containing 5% CO2.
Reagents and antibodies
The following reagents were purchased from Sigma-
Aldrich (St-Louis, MO, USA): DHA (D7439), NAC
(A7250), 3MA (M9281), rapamycin (R0395), and SP600125
(S5567). The following antibodies were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA, USA): JNK (sc-
7345), p-JNK (sc-6254), and β-actin (sc-130301). The fol-
lowing antibodies were purchased from Cell Signaling
Technology (Danvers, MA, USA): caspase-3 (9665), LC3
(2775), and Beclin 1 (3738).
Cell proliferation assay
Cells were plated in 96-well or 6-well cell culture plates
(5 × 103 cells per well) and treated with various com-
pounds, as indicated in the figure legends. At the end of
treatments, cell proliferation was evaluated using a Cell
Counting Kit-8 (CCK-8, CK04-13, Dojindo Molecular
Technologies, Kimamoto, Japan) or Crystal Violet
(C6158, Sigma) staining according to the instructions of
the manufacturer, or by photometric measurements to
determine cell viability. Three or four independent ex-
periments were performed for each assay condition.
Electron microscopy
Cells were harvested by trypsinization, fixed in 2.5% glu-
taraldehyde/4% paraformaldehyde in 0.1 mol/L cacody-
late buffer and then postfixed in 1% osmium tetroxide
buffer. After dehydration in acetone, cells were embed-
ded in spur resin, and thin sections (90 nm) were cut
using a Reichert Ultracut E microtome. The sectioned
grids were stained with a saturated solution of uranyl
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80 kV using a JEOL 1200EX transmission electron
microscope.
Western blot analysis
Cells were pelleted at 500 g for 5 min and lysed in cold lysis
buffer [20 mmol/L Tris–HCl (pH 7.5), 150 mmol/L NaCl,
1 mmol/L EDTA, 1 mmol/L EGTA, 1% Triton X-100,
2.5 mmol/L sodium PPi, 1 mmol/L β-glycerolphosphate,
1 mmol/L Na3VO4, 1 μg/mL leupeptin, and 1 mmol/L phe-
nylmethylsulfonyl fluoride]. After sonication for 5 s, lysates
were clarified by centrifugation at 12,000 g for 30 min at
4°C. Identical amounts (25 μg of protein) of cell lysates
were separated by 8% or 15% SDS-PAGE gel electrophor-
esis, and the proteins were transferred onto nitrocellulose
or polyvinylidene difluoride membranes. Membranes were
then incubated in a blocking solution consisting of 5%
powered milk in TBST [10 mmol/L Tris–HCl (pH 8.0),
150 mmol/L NaCl, and 0.1% Tween 20] for 1 h, followed
by immunoblotting with the respective antibodies. The pro-
teins of interest were detected using enzyme-linked chemi-
luminescence, according to the manufacturer’s protocol.
Transfection of siRNA
The target sequence for the JNK1/2-specific siRNA was 5’-
AAA AAG AAU GUC CUA CCU UCU-3’ (GeneBank ac-
cession number NM002750.2), the target sequence for the
Beclin 1-specific siRNA was 5’-UGG AAU GGA AUG
AGA UUA ATT-3’ (GeneBank accession number
NM003766.2) and the target sequence for the Atg-5-
specific siRNA was 5’-TGT GAT GTT CCA AGG AAG
AGC-3’ (GeneBank accession number NM004849.2). The
control siRNAs (no silencing) for these siRNAs were syn-
thesized by GenePharma Co. (Shanghai, China). siRNAs
were transfected into the cells using Lipofectamine 2000
(Invitrogen) according to the protocol provided by the
manufacturer.
Determination of intracellular ROS production
Production of intracellular ROS was measured using the
fluorescent dye 2,7-dichlorofluorescein diacetate (DCF-
DA). The cells were plated at a density of 1 × 105 in 6-
well plates, allowed to attach overnight, and exposed to
the treatments described in the figure legends. The cells
were then incubated with 10 M DCFHDA for 20 min at
37°C in a 5% CO2 incubator, washed and resuspended in
PBS at 1 × 106 cells/ml. The cells were analyzed by FACS
flow cytometry at an excitation wavelength of 514 nm,
and the fluorescence intensity of DCF was measured at
an emission wavelength of 525 nm. Untreated cells
served as controls. The amount of intracellular ROS was
expressed as the fold-increase of DCF fluorescence com-
pared with the control.Analysis of autophagy by GFP-LC3 redistribution
To monitor the formation of GFP-LC3 puncta, the cells
were transiently transfected with 1.0 mg GFP-LC3 plas-
mid, and then treated as described in the figure legends.
After treatment, autophagy was measured by light
microscopic quantification of cells transfected with GFP-
LC3, as previously described [33].
Statistical analysis
Results are expressed as mean ± SD. Statistical analysis
was performed using the Student’s t test, with P < 0.05
deemed as statistically significant. All experiments were
repeated at least three times.
Results
DHA possesses cytotoxic effects on pancreatic cancer
cells
DHA is cytotoxic for a variety of types of cancer cells,
while essentially having no effect in normal cells [25-28].
To determine DHA effects on pancreatic cancer cells,
we treated BxPC-3 and PANC-1 human pancreatic can-
cer cells with different concentrations of DHA for 24 h.
This treatment was followed by a cell proliferation and
cytotoxicity assay (CCK-8) to assess cell viability. DHA
significantly inhibited the growth of the pancreatic can-
cer cells, and DHA cytotoxicity in these cells was dose-
and time-dependent (Figure 1A and B). We used a clo-
nogenic assay to confirm the effects of DHA on these
cell lines and to determine whether DHA affected long-
term colony formation; the number of surviving colonies
was also markedly inhibited (Figure 1C). These results
indicate that DHA has a specific effect on human pan-
creatic cancer cell lines.
Treatment with DHA induces caspase-3-dependent cell
death and autophagy in pancreatic cancer cells
To determine if apoptosis depends on caspase-3, we first
assessed caspase-3 cleavage, an essential step in the cas-
pase pathway. A western blot analysis in DHA-treated
cells revealed decreased procaspase-3 levels, and in-
creased levels of the cleaved, active forms (Figure 2A).
Following DHA treatment, we detected caspase-3 cleav-
age in the two cancer cell lines for all concentrations
and time (Figure 2A and B).
We next determined whether DHA treatment induced
autophagy in tumor cells. The autophagy marker LC3-II, a
cleaved and then conjugated to phosphatidylethanolamine
product of microtubule-associated protein 1 light chain 3,
was assessed in an immunoblotting assay. After DHA treat-
ment, LC3-II was dose- and time-dependently increased in
BxPC-3 and PANC-1 cells (Figure 2A and B). Autophagy
induction by DHA was confirmed by electron microscopy
and a GFP-LC3 cleavage assay, which showed abundant
double-membrane vacuoles (Figure 2C) and an increased
Figure 1 Cell death induced by DHA in pancreatic cancer cells. (A, B) BxPC-3 and PANC-1 cells were treated with different concentrations of
DHA for 24 h, or treated with 50 μmol/L DHA for different times. The percentage of cell death was determined by a CCK-8 assay. (C) BxPC-3 and
PANC-1 cells were treated with different concentrations of DHA for 24 h and washed with PBS. Cells were then incubated for an additional 7 d
and stained with crystal violet, as described in the Materials and methods section.
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cytoplasm of DHA-treated cells. In contrast, these vacuoles
were rarely observed in vehicle-treated pancreatic cancer
cells (Figure 2C).
To evaluate the role of DHA-induced autophagy, we
treated cells with 3MA, an inhibitor of autophagy, to
further decrease autophagy in the pancreatic cancer cells
during DHA treatment. The inhibition of DHA-induced
autophagy by 3MA significantly increased the expression
of cleaved caspase-3 (Figure 2E).
To further confirm whether autophagy protected the
pancreatic cancer cells from DHA-induced apoptosis,
the effect of 3MA (an autophagy inhibitor) and rapamy-
cin (an autophagy activator) on DHA-induced cell death
was examined. Autophagy inhibition significantly in-
creased the incidence of cell death, whereas autophagy
activation decreased cell death, as assessed by a CCK-8
assay (Figure 2F). Additionally, we also found that
knockdown of Atg5 did not change the effect of DHA
on cell viability (Figure 2F). These findings indicate that
DHA induced some kind of protective, pro-survivalautophagy increasing the resistance of the cancer cells
against DHA therapy. The induction of autophagy was
independent on Atg5. This increase in cell death via au-
tophagy inhibition would lead to the inhibition of tumor
growth.
Treatment with DHA activates JNK and beclin 1 in
pancreatic cancer cells
DHA activates mitogen-activated protein kinase
(MAPK) signaling pathways in a number of cell
types. To study the MAPK/JNK signaling pathway in
DHA-induced autophagy, we first measured JNK ac-
tivation by DHA. DHA stimulated JNK phosphoryl-
ation in a dose- and time-dependent manner in the
two cell lines (Figure 3A).
The induction of autophagy by DHA was con-
firmed previously. To determine if DHA upregulated
Beclin 1 expression in BxPC-3 and PANC-1 cells,
Beclin 1 protein expression was measured. Immuno-
blotting revealed dose- and time-dependent increases
in Beclin 1 expression in cells exposed to DHA
Figure 2 DHA triggers apoptosis and autophagy in pancreatic cancer cells. (A, B, E) Immunoblot analysis of LC3 and caspase-3 levels in
BxPC-3 and PANC-1 cell lines treated with different concentrations of DHA for 24 h, or treated with 50 μmol/L DHA for different times in the
presence or absence of 10 mmol/L 3MA. (C) Representative electron micrographs of BxPC-3 cells treated with 50 μmol/L DHA for 24 h in the
presence or absence of 10 mmol/L 3MA. (D) Top, representative images of GFP-LC3 staining in BxPC-3 cells transfected with the GFP-LC3 plasmid,
followed by 50 μmol/L DHA for 24 h with or without 3MA (10 mmol/L); bottom, number of GFP-LC3 dots scored in 100 transfected cells. Bar:
5 μm. (F) BxPC-3 and PANC-1 cells were treated with 50 μmol/L DHA for 24 h in the presence or absence of 10 mmol/L 3MA or 1 μmol/L
rapamycin or Atg 5 siRNA. The percentage of dead cells was determined by a CCK-8 assay. *P < 0.05; **P < 0.01.
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ment with DHA activates JNK and Beclin 1 in both
pancreatic cancer cell lines in a dose- and time-
dependent manner.Up-regulation of JNK expression following DHA treatment
depends on ROS
JNK pathway over-activation is crucial to many pro-
cesses leading to cell death, including chronic and acute
Figure 3 The effect of DHA on JNK phosphorylation and the
up-regulation of Beclin 1 expression in pancreatic cancer cells.
(A, B) BxPC-3 and PANC-1 cells were treated with various concentra-
tions of DHA for 24 h or with 50 μmol/L DHA for different times.
The expression levels of JNK, phospho-JNK, and Beclin 1 protein
were analyzed by immunoblotting (A). After treatment with DHA for
different times, cell lysates were analyzed by immunoblotting using
antibodies against JNK, phospho-JNK, and Beclin 1 (B).
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ing via the activation of upstream kinases or the inacti-
vation of phosphatases, other unknown mechanisms are
likely to contribute to ROS-induced JNK increases in
pancreatic cancer cells. To exclude the possibility that
other mechanisms were responsible for our observa-
tions, we measured ROS levels in response to DHA.
ROS were increased after DHA treatment and did not
differ between the two tested cell lines (Figure 4A).
To further determine whether DHA treatment requires
JNK activation to generate ROS, we pre-treated BxPC-3
cells with SP600125 (a specific JNK inhibitor) for 1 h, be-
fore exposing them to DHA. In contrast to DHA treatment
alone, SP600125 pretreatment prevented alterations in ROS
levels (Figure 4B). To examine whether ROS inhibition im-
pacted JNK signaling, we compared JNK activation with or
without N-acetyl-L-cysteine (NAC, a ROS inhibitor). NAC
pretreatment significantly lowered intracellular ROS com-
pared with DHA-treated cells (Figure 4C). More import-
antly, the degree of JNK activation after DHA treatmentwas decreased in the cells pretreated with NAC (Figure 4D),
and this decreased JNK activation was related to the inhib-
ition of ROS formation. These results indicate that JNK ex-
pression following DHA treatment depends on ROS.
Inhibition of JNK expression down-regulates beclin 1 and
reduces autophagy
To further assess the role of JNK in DHA-induced au-
tophagy, cells were pretreated with SP600125 (10 mM)
for 1 h, and were then exposed to DHA. In contrast to
DHA alone, SP600125 pretreatment blocked the increase
in LC3-II induced by DHA (Figure 5A). Furthermore,
SP600125 treatment decreased the punctate foci of LC3
in the cytoplasm (Figure 5B).
To determine if JNK activation is required for Beclin 1
expression in the context of DHA-induced autophagy,
JNK expression was knocked-down using a siRNA di-
rected against JNK1/2. siRNA transient transfection
down-regulated JNK (Figure 5C). More importantly,
siRNA-mediated JNK down-regulation prevented the
DHA-induced up-regulation of Beclin 1 protein in
addition to efficiently inhibiting the level of JNK phos-
phorylation in pancreatic cancer cells (Figure 5C). These
findings suggest that JNK could be directly involved in
the DHA-induced increased Beclin 1 expression.
To test whether blockage of DHA-activated autophagy
through JNK inhibition could enhance cytotoxicity,
tumor cells were transfected with a non-targeting RNA
or a siRNA targeting JNK, and were then exposed to
DHA. DHA cytotoxicity was significantly increased by
silencing the expression of JNK in these cells (Figure 5D).
Taken together, these findings indicate that JNK could
be directly involved in the DHA-induced increased
Beclin 1 expression. Furthermore, it can be concluded
that the inhibition of JNK could enhance the efficacy of
DHA by inhibiting autophagy.
Beclin 1 siRNA knock-down blocks DHA-induced
autophagy
To potentially use the intrinsic role of Beclin 1 in DHA-
induced autophagy, we investigated the effects of Beclin
1 knock-down on DHA-induced apoptosis. We designed
siRNAs down-regulating Beclin 1 expression. Beclin 1 si-
lencing significantly inhibited LC3-II induction by DHA
(Figure 6A). Fewer Beclin 1-silenced cells exhibited
GFP-LC3 punctae compared to the control DHA- and
siRNA-treated cells (Figure 6B). These results suggest
that Beclin 1 could play a crucial role in DHA-induced
autophagy.
Discussion
The association between apoptosis and autophagy re-
mains controversial. Experimental evidences suggest that
autophagy can mediate apoptosis, and that autophagy
Figure 4 JNK expression induced by DHA is dependent on ROS generation. (A) BxPC-3 and PANC-1 cells were treated with 50 μmol/L DHA
for different times, and then subjected to flow cytometry to measure ROS levels, as described in the Materials and Methods section. (B, C) BxPC-3
and PANC-1 cells were treated with 50 μmol/L DHA for 24 h in the presence or absence of 10 μmol/L SP600125 or 10 mmol/L NAC pretreatment
for 1 h and then subjected to flow cytometry to measure the levels of ROS. (D) immunoblot analysis of the phospho-JNK levels in BxPC-3 and
PANC-1 cells treated with the indicated concentrations of DHA for 24 h in the presence or absence of 10 mmol/L NAC. *P < 0.05.
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with apoptosis and necrosis [34]. However, several stud-
ies demonstrated that autophagy would also be critical
for cell survival [35-37]. Our research group has exten-
sively studied the effect of the anticancer agent DHA on
pancreatic cancer cells, and we showed that DHA sig-
nificantly inhibited cell growth and induced apoptosis in
pancreatic cancer cells [38]. Interestingly, DHA treat-
ment also induces autophagy in pancreatic cancer cells.
Therefore, in the present study, we explored the role of
autophagy induced by DHA and its mechanisms in pan-
creatic cancer cells.
Autophagy may be used by some cancer cells types as
a mean to adapt to the stressful environment observed
within solid tumors (i.e. hypoxic, nutrient-limiting, and
metabolically stressful), as well as in artificial conditions
induced by cytotoxic agents [39]. Studies in human can-
cer cell lines showed that a number of anticancer ther-
apy modalities, including radiations and chemotherapy
induced autophagy as a protective mechanism aiming
toward survival [30,31]. Moreover, in cancer cell lines,
inhibition of autophagy may be a therapeutic target
under some circumstances. Indeed, inhibiting autophagy
has been shown to enhance cancer cells’ therapies such
as DNA-damaging agents, hormone therapies for breast
and ovarian cancer, and radiations [40-43]. In thepresent study, we used 3MA (an autophagy inhibitor) to
inhibit DHA-induced autophagy and rapamycin (an au-
tophagy activator) to enhance it. The data clearly dem-
onstrated that DHA can induce autophagy and that
inhibition of autophagy can enhance the sensitivity of
pancreatic cancer cells to DHA. These findings showed
that DHA therapy induced a kind of protective autoph-
agy in pancreatic cancer cells, increasing their resistance
to DHA and hence their survival, and that inhibiting au-
tophagy may led to increased apoptosis. Such enhanced
apoptosis should normally reduce tumor growth.
The excessive production of ROS can overcome cells’
defenses against ROS, thus leading to oxidative stress,
which is involved in cell injury and apoptosis. Studies
showed that DHA led to ROS generation in papilloma
virus-expressing cell lines, inducing oxidative stress and,
ultimately, apoptosis [25]. Recent studies in models of
hepatocyte oxidative stress emphasized that the super-
oxide generator menadione mediated the activation of
MAPK/JNK and c-Jun [44,45]. ROS is known to increase
JNK by activating upstream kinases or by inactivating
phosphatases, but other unknown mechanisms might
contribute to DHA- and ROS-induced increases in JNK.
In our study, we confirmed that the up-regulation of
JNK expression following DHA treatment depended on
ROS. Accordingly, several studies demonstrated that
Figure 5 Inhibition of JNK expression downregulates Beclin 1 and represses autophagy. (A) BxPC-3 and PANC-1 cells were treated with
different concentration of DHA for 24 h in the presence or absence of 10 μmol/L SP600125 pretreatment for 1 h. The expression levels of the
LC3-I and LC3-II proteins were subsequently analyzed by immunoblotting. (B) BxPC-3 cells transfected with the GFP-LC3 plasmid, followed by
50 μmol/L DHA for 24 h with or without SP600125 (10 μmol/L). The number of GFP-LC3 dots was subsequently scored in 100 transfected cells.
(C) BxPC-3 cells were treated with 50 μmol/L DHA for 24 h in the absence or presence of JNK1/2 siRNA. The expression levels of phospho-JNK
and Beclin 1 protein were subsequently analyzed by immunoblotting. (D) BxPC-3 cells transfected with a non-targeting RNA or a JNK1/2-targeted
siRNA were treated with 50 μmol/L DHA for 24 h. At the end of the treatment, cell viability was measured using a CCK-8 assay. *P < 0.05.
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forms of hepatocyte apoptosis, including the forms in-
duced by chronic and acute stress from ROS [46,47].
Therefore, we conclude that the generation of ROS also
contributes to JNK activation following DHA treatment.
The resolution of the function of JNK in autophagy
regulation is imminent. It was observed that autophagy
associated with endoplasmic reticulum stress (ERS) wasFigure 6 Beclin 1 is required for DHA-induced autophagy. (A) BxPC-3
were treated with 50 μmol/L DHA for 24 h. At the end of treatment, the ex
by immunoblotting. (B) BxPC-3 cells transfected with the GFP-LC3 plasmid
Beclin 1 siRNA. The number of GFP-LC3 dots was subsequently scored in 1inhibited in IRE1-deficient cells or in cells treated with a
JNK inhibitor, suggesting that IRE1-JNK is required for
ERS-induced autophagy [32]. These data suggest that
JNK may play a crucial role in autophagy. In this study,
we showed that DHA activated the JNK pathway and
mediated autophagy. We showed that DHA increased
JNK phosphorylation in pancreatic cancer cells in a
time- and dose-dependent manner. Activation of thecells transfected with a non-targeting RNA or a Beclin 1-targeted siRNA
pression levels of the Beclin 1, LC3-I, and LC3-II protein were analyzed
, followed by 50 μmol/L DHA for 24 h in the absence or presence of
00 transfected cells. *P < 0.05.
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known to enhance autophagy by disrupting the Bcl-2/
Beclin 1 competitive interaction [33]. Bcl-2 is able to
regulate Beclin 1-induced autophagy by directly binding
to Beclin 1, and thus preventing its activation [48]. Simi-
larly, we observed that JNK was involved in Beclin 1 ex-
pression, which then played a crucial role in protective
autophagy in DHA-induced cancer cells. Although,
Beclin 1 up-regulation by JNK was observed after au-
tophagy induced by the anticancer drug topotecan, the
data presented in the present study constitute the first
evidence that Beclin 1 is regulated by JNK in pancreatic
cancer cells.
Conclusions
Our results suggest that autophagy was induced by
DHA in the studied human pancreatic cancer cell lines.
DHA also activated JNK, thus up-regulating Beclin 1.
JNK activation primarily depends on ROS, which is gen-
erated by DHA treatment. Moreover, inhibiting the JNK
pathway and silencing Beclin 1 expression could inhibit
DHA-induced autophagy. These results suggest that au-
tophagy can be induced by DHA through Beclin 1 ex-
pression induced by JNK. Silencing of JNK kinase may
constitute appealing therapeutic target for a generalized
strategy to treat cancer through blunting of autophagy.
This may support a novel therapeutic strategy against
pancreatic cancer in clinical settings.
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